Chronic Obstructive Pulmonary Disease Drugs Market Size, Share and Global Trend By Drug Class (Bronchodilators, Steroids, Combination drugs), By Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy), and Regional Forecast, 2024-2032

In February 2019, FDA approved the use of Yupelri inhalation solution manufactured by Mylan for patients suffering from chronic obstructive pulmonary disease. According to the World health Organisation (WHO), chronic obstructive pulmonary disease (COPD) is a type of life-threatening lung disorder that disrupts the lung airflow and interferes with normal breathing.

The major factors that cause COPD are exposure to cigarette smoke, air pollution, chemical fumes or dust, rare genetic condition, among others. Recent studies (2018) published in The Lancet Respiratory Medicine, revealed that permanent lung damage caused due to COPD starts even before the patient experience any symptoms.

The Global Burden of Disease Study (2016) performed by the Institute of Health Metrics and Evaluation, reported 251 million incidences of COPD globally. According to WHO, globally approximate 200 million people were diagnosed with COPD in the year 2016. Urbanization in developing countries in the Asia Pacific exposes the population to various forms of lung irritants that could be a major risk factor to cause COPD.

The World Health Organisation (WHO) states that the most common cause of COPD is exposure to tobacco smoke both via first hand and second-hand smoking. This global increase in the prevalence of COPD is expected to drive the COPD drugs market growth during the forecast period.

The high economic burden in the treatment of COPD is expected to harm the growth of the global COPD drugs market. Centre for Disease Control and Prevention (CDCP) attributed that the cost related to COPD in the US were 32.1 $ billion in the year 2010 and is projected to increase to 49 billion by the year 2020.

Key Players Covered

Key players operating in the global chronic obstructive pulmonary disease drugs market are Mylan N.V., GlaxoSmithKline plc., Boehringer Ingelheim Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca Pharmaceuticals LP, and others.

SEGMENTATION

At present, among drug class segment, bronchodilators are considered to hold the major share of the COPD drugs market due to the increased efficacy of the drug class that could lead to a rise in adoption of the therapy globally.

Key Insights

• Pipeline analysis


• Prevalence of COPD


• Overview of the regulatory scenario for key countries


• Pricing analysis of key market players


• Key collaborations of companies

Regional Analysis

The global COPD drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global COPD drugs market owing exponentially increasing air pollution, the rapid pace of industrialization, and the adoption of a sedentary lifestyle. Moreover, growth in the smoking population and lack of awareness of COPD is expected to raise the prevalence of the disease, resulting in increased adoption of COPD drugs. According to The Lung Association, COPD is prevalent in men and women and is the sixth most common factor of hospitalization in women and fourth most in men in Canada. The Asia Pacific, Middle East, and Africa also hold huge potential for growth of the global COPD drugs owing to the rising prevalence of respiratory distress conditions. For instance, the data published by the World health organization (WHO) states that more than 90% of death due to COPD happen in low and middle-income countries. Rapid urbanization that causes an increase in air pollution provides amplifies predisposition to acquire respiratory diseases like COPD, hence providing lucrative growth opportunities for COPD drugs market in these regions.

COPD Drugs Industry Developments

• In July 2018, FDA advisory committee voted against the approval of GSK’s mepolizumab (Nucala) as add on treatment for patients suffering from COPD.
• In September 2017, TRELEGY ELLIPTA developed by GSK in collaboration with Innoviva was approved by the U.D FDA for use in patients suffering from COPD.
• In September 2014, Boehringer Ingelheim received U.S FDA approval for SPIRIVA RESPIMAT for long term treatment of bronchospasm associated with COPD.
• In January 2019, The European Commission approves Bevespi Aerosphere (glycopyrronium/formoterol fumarate) developed by AstraZeneca indicated for adults with COPD.